Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
11/2003
11/13/2003WO2003042244A3 Immunogenic mimetics of multimer proteins with promiscuous t cell epitope inserts
11/13/2003WO2003031459A3 Modulation of the expression of genes dependent on stat-1
11/13/2003WO2003030944A3 Inhibition of stat-1
11/13/2003WO2003028657A9 Compositions for oral gene therapy and methods of using same
11/13/2003WO2003028536A3 Methods for diagnosing and treating heart disease
11/13/2003WO2003027316A3 Methods of using 33751, a human potassium channel family member
11/13/2003WO2003024502A3 Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream
11/13/2003WO2003018134A3 Bioadhesive compositions and methods for enhanced mucosal drug absorption
11/13/2003WO2003012111A3 Conjugates for the modulation of immune responses
11/13/2003WO2003006657A3 Gene-regulatory elements for gene therapy, for the prevention and diagnosis of metastases and for the gene therapy of tumours
11/13/2003WO2003000918A3 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof
11/13/2003WO2003000889A3 Identification of ses-1 and the uses of the same
11/13/2003WO2003000227A3 A method for preparation of vesicles loaded with biological material and different uses thereof
11/13/2003WO2002098443A3 Stabilised mrna with an increased g/c content and optimised codon for use in gene therapy
11/13/2003WO2002097056A3 Method for generating replication defective viral vectors that are helper free
11/13/2003WO2002083920A3 Nucleic acid sequences useful in the detection and treatment of various cancers
11/13/2003WO2002079402A3 Method of inhibiting cancerous cell proliferation using ras mutants of gdp-bound conformation
11/13/2003WO2002066648A3 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof
11/13/2003WO2002061033A3 Transfection of human embryonic stem cells
11/13/2003WO2002057302A8 A virus causing respiratory tract illness in susceptible mammals
11/13/2003WO2002014362A3 A hepatitis c virus non-structural ns3/4a fusion gene
11/13/2003WO2002014348B1 Glycoproteins and methods of use thereof
11/13/2003WO2000021978A3 Laminin 5, 13 and 14 and uses thereof
11/13/2003US20030213006 Nucleotide sequences comprised of human chorionic gonadotropin (HCG) regulatory sequences for treating and preventing tumors via gene expression inhibition; drug screening
11/13/2003US20030213004 Composition comprising ribozyme/monoclonal antibody fusion protein for treating cell proliferative disorders; anticarcinogenic/antiproliferative agents
11/13/2003US20030212266 Growth arrest homeobox gene
11/13/2003US20030212032 Oligonucleotide N3'→P5' thiophosphoramidates: their synthesis and use
11/13/2003US20030212030 Blood disorders; synergistic mixture of vector and monoclonal antibody
11/13/2003US20030212026 Induce immunology response
11/13/2003US20030212025 Cd154 variants
11/13/2003US20030212023 Invention provides cDNAs encoding deoxyribonuclease II beta and isolated, purified deoxyribonuclease II beta proteins and antibodies against this protein and antisense agents targeted to cDNA or mRNA encoding deoxyribonuclease II beta
11/13/2003US20030212022 Injectable; mixture containing hydrophilic, biocompatibility polymer spherical particles, active material and transfection agent; anticancer agents
11/13/2003US20030212021 Myeloid colony stimulating factor and uses thereof
11/13/2003US20030212020 Antisense modulation of macrophage migration inhibitory factor expression
11/13/2003US20030212019 Hybrid nucleic acid; anticancer agents
11/13/2003US20030212018 Antisense modulation of mekk2 expression
11/13/2003US20030212017 Antisense modulation of farnesyl transferase beta subunit expression
11/13/2003US20030211984 Genetic engineering; antibodies; libraries
11/13/2003US20030211614 Using genetically engineered adeno-associated viral vector to transfer hereditary material into cells; gene therapy
11/13/2003US20030211613 Methods of altering calcium transport
11/13/2003US20030211609 Antisense modulation of ara70 expression
11/13/2003US20030211608 Antisense modulation of glycogen synthase kinase 3 beta expression
11/13/2003US20030211607 Antisense modulation of survivin expression
11/13/2003US20030211605 Derivation of midbrain dopaminergic neurons from embryonic stem cells
11/13/2003US20030211598 Administering antitumor agents to tissues having an epithelial membrane; drug delivery; gene therapy
11/13/2003US20030211583 Egs molecules that specifically downregulae bcl-xl experession
11/13/2003US20030211582 Human DNA Ligase III
11/13/2003US20030211541 Using immunological means to identify growth differentiation factor-14 (GDF-14) for treating cell proliferative and immunological disorders; gene expression inhibition; antiproliferative agents
11/13/2003US20030211540 Treatment of insulin resistance
11/13/2003US20030211521 Breast cancer antigen
11/13/2003US20030211515 Comprises nucleotide sequences coding matrix protein for diagnosing and treating cancer
11/13/2003US20030211513 Intracellular signaling proteins
11/13/2003US20030211143 Emulsion and micellar formulations for the delivery of biologically active substances to cells
11/13/2003US20030211141 Genetic and protein manipulation of betaIG-H3 for the treatment and cure of muscular dystrophies
11/13/2003US20030211100 Gene therapy; nucleic acid coding immunoglobulins; anticancer agents
11/13/2003US20030211099 Blocking leukocyte emigration and inflammation by interfering with cd99/hec2
11/13/2003US20030211092 Genetic engineering; gene expression; culture product
11/13/2003US20030211085 Cell therapy for chronic stroke
11/13/2003US20030211080 Congestive heart failure; monitoring gene expression; supplying adeno-associated viral vector
11/13/2003US20030211065 Alopecia; mutant gene
11/13/2003CA2495787A1 Methods for delivering nucleic acid molecules into cells and assessment thereof
11/13/2003CA2494542A1 Preventing secondary lymphedema with vegf-d dna
11/13/2003CA2491708A1 Non-viral gene delivery system
11/13/2003CA2487274A1 Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
11/13/2003CA2485216A1 Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
11/13/2003CA2485110A1 Expression system for large functional proteins
11/13/2003CA2484538A1 Vectors with modified protease-dependent tropism
11/13/2003CA2484425A1 Fusions of cytokines and tumor targeting proteins
11/13/2003CA2484287A1 Pharmaceutical- or gene-carrier compositions with reduced hemagglutinating activity
11/13/2003CA2484251A1 Materials and methods for inhibition of respiratory syncytial virus infection
11/13/2003CA2484185A1 Site specific listeria integration vectors and methods for using the same
11/13/2003CA2483996A1 Promoters exhibiting endothelial cell specificity and methods of using same
11/13/2003CA2483915A1 Vectors having both isoforms of b-hexosaminidase
11/13/2003CA2483909A1 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
11/13/2003CA2483838A1 Chemically activated carboxypolysaccharides and uses
11/13/2003CA2483050A1 Optimization of transgene expression in mammalian cells
11/13/2003CA2480008A1 Use of il-13 receptor subunit alpha 2 as an anti-cancer vaccine
11/13/2003CA2462879A1 Immunoconjugates for the treatment of tumours
11/12/2003EP1361277A1 Optimization of transgene expression in mammalian cells
11/12/2003EP1361269A1 Delivery of gene products via mesangial cells expressing an exogenous gene
11/12/2003EP1360965A1 Methods of treating diseases in association with decrease in the expression of aop-1 gene or aop-1 and remedies for the diseases
11/12/2003EP1360898A1 Joint utilization of the insulin gene and the glucokinase gene in the development of therapeutic approaches for diabetes mellitus
11/12/2003EP1360498A2 Latent human tuberculosis model, diagnostic antigens, and methods of use
11/12/2003EP1360319A2 Diagnosis of diseases associated with metabolism
11/12/2003EP1360307A2 Chimeric polypeptides of serum albumin and uses related thereto
11/12/2003EP1360293A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
11/12/2003EP1360291A2 Human polynucleotides and polypeptides encoded thereby
11/12/2003EP1360205A1 Angiogenesis-inhibitory tripeptides, compositions and their methods of use
11/12/2003EP1360198A2 Novel polypeptides and nucleic acids encoded thereby
11/12/2003EP1360191A2 Methods and compositions for expressing polynucleotides specifically in smooth muscle cells in vivo
11/12/2003EP1359932A2 Tip39 polypeptides
11/12/2003EP1112083B1 Use of an angiogenic factor for the treatment of microvascular angiopathies
11/12/2003EP0897390B1 Human tumor necrosis factor delta and epsilon
11/12/2003EP0847272B1 LIPOSOMAL p-ETHOXY OLIGONUCLEOTIDES
11/12/2003EP0775203B1 Method of gene therapy using dna vectors without selection marker gene
11/12/2003EP0759759B1 P75 tnf receptor promoters
11/12/2003CN1455819A Nucleic acid relating to disease
11/12/2003CN1455682A Compositions for gene therapy of rheumatoid arthritis including gene encoding anti-angiogenic protein or parts thereof
11/12/2003CN1455674A Use of sheep's parapoxvirus bacterial strain for preparing anti-virus medicines and anti-cancer medicine
11/12/2003CN1127343C Myoblast therapy for mammalian diseases
1 ... 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 ... 870